Notes on Module One: Introduction to Drug Use and Abuse — Rates and Patterns (Comprehensive Summary)

Correlates of Drug Use

  • Correlate: a variable that is statistically related to another variable (e.g., drug use).
  • Important distinction: correlates are NOT necessarily causes.
  • Major categories discussed:
    • Risk factors
    • Protective factors
  • Also covered: antecedents, prevalence rates, continuance (loyalty) rates, consumption levels, and life-cycle rates.

Correlates of Drug Use

  • Definition recap: a correlate is a variable statistically related to drug use, but correlation ≠ causation.
  • Key takeaway: identifying correlates helps predict risk and protective contexts, not prove that a factor causes drug use.

Risk Factors of Drug Use

  • Person-related: variables that correlate with higher use/abuse
    • Positive beliefs about drug use
    • Mental illness
    • Personality traits (e.g., impulsivity, risk-taking, aggression)
  • Social situation: higher risk when surrounded by certain social contexts
    • Peers who use drugs
    • Peer pressure
    • Social norms that favor drug use
    • Lack of social support or healthy coping skills
  • Environmental: external conditions that facilitate use
    • Accessibility/availability of drugs
    • Positive media portrayals of drug use
    • Inadequate drug education or prevention programs

Protective Factors of Drug Use

  • Variables that correlate with lower use/abuse
  • Person-related: higher perceived risk; higher risk aversion
  • Social-related: positive family bonds (attachment, support, communication, involvement); non-using peers
  • Environmental: integration into social institutions (family, school, work); commitment to conventional activities (academics, extracurriculars); religious affiliation/participation

Variation in Drug Use Patterns by Characteristics

  • Patterns vary by:
    • Gender
    • Race and ethnicity
    • Level of education
    • Personality variables (e.g., impulsivity)
    • Genetics

Race/Ethnicity and Past-Year Use (NSDUH 2021)

  • Figure references show differences in past-year illicit drug use and marijuana use by race/ethnicity among people aged 12+; note:
    • Error bars represent 99% confidence intervals; wider bars = less precision.
    • Large apparent group differences may not be statistically significant.
  • Key note on data interpretation: not all groups have precise estimates due to sample sizes in some categories.

NSDUH 2021 Table 1.3: Illicit Drug, Marijuana, Cocaine, and Crack Use by Race/Ethnicity (Past Year, Aged 12+)

  • Estimates are percentages with standard errors in parentheses.
  • Illicit Drug Use (Past Year) by race/ethnicity:
    • TOTAL: 21.9% (SE 0.33)
  • Marijuana Use (Past Year) by race/ethnicity:
    • TOTAL: 18.7% (SE 0.32)
  • Cocaine Use (Past Year) by race/ethnicity:
    • TOTAL: 1.7% (SE 0.09)
  • Crack Use (Past Year) by race/ethnicity:
    • TOTAL: 0.4% (SE 0.05)
  • By race/ethnicity (Past Year Illicit Drug Use):
    • Not Hispanic or Latino: 22.4% (SE 0.35)
    • White: 22.5% (SE 0.42)
    • Black or African American: 24.3% (SE 0.85)
    • American Indian or Alaska Native (AIAN): 36.1% (SE 4.17)
    • Native Hawaiian or Other Pacific Islander (NHOPI): data suppressed (*
      *)
    • Asian: 11.1% (SE 0.98)
    • Multiracial: 34.6% (SE 2.25)
  • By race/ethnicity (Past Year Marijuana Use):
    • Not Hispanic or Latino: 19.4% (SE 0.35)
    • White: 19.5% (SE 0.41)
    • Black or African American: 21.3% (SE 0.83)
    • AIAN: 35.0% (SE 4.14)
    • NHOPI: data suppressed (* )
    • Asian: 8.6% (SE 0.89)
    • Multiracial: 30.7% (SE 2.18)
  • By race/ethnicity (Past Year Cocaine Use):
    • Not Hispanic or Latino: 1.7% (SE 0.09)
    • White: 1.7% (SE 0.10)
    • Black or African American: 1.7% (SE 0.27)
    • AIAN: 2.8% (SE 1.14)
    • NHOPI: (*)
    • Asian: 1.0% (SE 0.30)
    • Multiracial: 3.2% (SE 0.66)
  • By race/ethnicity (Past Year Crack Use):
    • Not Hispanic or Latino: 0.4% (SE 0.05)
    • White: 0.3% (SE 0.06)
    • Black or African American: 0.9% (SE 0.22)
    • AIAN: (*)
    • NHOPI: (*)
    • Asian: 0.1% (SE 0.08)
    • Multiracial: 1.0% (SE 0.38)
  • Notes:
    • Some cells have low precision; estimates may be withheld.
    • See Detailed Tables for full methodology and definitions.

Limitations of Correlation Studies

  • Core limitation: correlation does not imply causation.
  • Examples of possible explanations for the marijuana-use–grades correlation:
    • Marijuana use may cause poor school performance.
    • Poor school performance may lead to marijuana use.
    • A third set of factors could influence both (e.g., socioeconomic status, family environment).
    • There may be reciprocal relationships (feedback loops).
    • Some relationships may be spurious (due to confounding factors).

Antecedents of Drug Use

  • Antecedent: a factor that occurs before initiation of drug use.
  • Important caveat: antecedents are not labeled as causes.
  • Examples of antecedents:
    • Aggressiveness
    • Conduct problems
    • Poor academic performance
    • Attachment to a drug-using peer group
    • Parental and community norms that support drug use

Multilevel Influences on Drug Use

  • Drug use is influenced by a complex, multilevel system including:
    • Laws and penalties
    • Societal availability and cost
    • Community and family
    • Family and peers
    • Political statements
    • Anti-drug commercials
    • Schools
    • Personal factors: knowledge, attitudes, beliefs
    • Personal drug experience, motives/needs
    • Biology
    • Media and cultural portrayals (e.g., alcohol/tobacco ads, movies, news)
    • Clubs/organizations, church, gangs, police, and authorities/celebrities statements
  • Conceptual takeaway: interactions across levels shape risk and protection in complex ways.

Costs of Drug Abuse to Society

  • Deaths
  • Emergency room visits
  • Drugs in the workplace and lost productivity
  • Broken homes, illnesses, shorter lives, etc.
  • Cost of maintaining the drug habit
  • Cost of drug-related criminal behavior
  • Cost of treating patients
  • Public nuisance or health hazards (e.g., spread of disease)
  • Other societal costs

Rates and Patterns of Drug Use: Basic Concepts

  • Four key concepts to understand rates/patterns:
    • Overall Prevalence Rates
    • Continuance (loyalty) Rates
    • Consumption Levels
    • Life-Cycle Rates

1) Overall Prevalence Rates

  • Prevalence rate: the percentage of a given population that has used a specific drug within a specified period.
  • Variation by drug
    • Can refer to a particular frequency (e.g., past-month prevalence)
    • Alcohol generally has the highest prevalence rate among psychoactive substances
    • Illicit drugs: marijuana typically has the highest prevalence among illicit drugs
  • Observation: some drugs have relatively low prevalence but large societal costs due to other factors (crime, health, etc.)

2) Continuance (LoYALty) Rates

  • Definition: Continuance Rate = for a given drug, the proportion of those who have used at least once who have used the drug more recently (typically in the past month or year).
  • Importance: Indicates regular use rather than experimental use.
  • Note: Legal drugs often have higher continuance rates than illegal drugs.
  • Example interpretation: If 100 lifetime users exist and 63 used in the past month, Continuance Rate ≈ R=PastextMonthextUseLifetimeextUse=63100=0.63.R = \frac{Past ext{ }Month ext{ }Use}{Lifetime ext{ }Use} = \frac{63}{100} = 0.63.
  • Table 1-1 (selected continuance rates, 2011):
    • Alcohol: Past Month / Lifetime ≈ 0.63
    • Cigarettes: Past Month / Lifetime ≈ 0.85
    • Marijuana: Past Month / Lifetime ≈ 0.61
    • Cocaine: Past Month / Lifetime ≈ 0.60
    • Pain Relievers: Past Month / Lifetime ≈ 0.40
    • LSD: Past Month / Lifetime ≈ 0.33
    • Tranquilizers: Past Month / Lifetime ≈ 0.35
    • Ecstasy: Past Month / Lifetime ≈ 0.22
    • Methamphetamine: Past Month / Lifetime ≈ 0.50
    • Crack: Past Month / Lifetime ≈ 0.33
    • Sedatives: Past Month / Lifetime ≈ 0.50
    • OxyContin: Past Month / Lifetime ≈ 0.33
    • Heroin: Past Month / Lifetime ≈ 0.50
  • Source: Table 1-1, 2011 NSDUH Detailed Tables, SAMHSA (2012).

3) Consumption Levels

  • Definition: Consumption levels = total volume of a given drug used during a given time period within a population.
  • Key idea:
    • A drug can have a high prevalence (many people use it) but low consumption per user, or vice versa.
    • Example: Prevalence: Alcohol > Cigarettes (more people drink alcohol than smoke cigarettes).
    • Consumption: Alcohol < Cigarettes in total volume because cigarette users, on average, use more per user than typical drinkers in some contexts.
  • Policy implication: Legalization often affects consumption levels more than prevalence rates, since fewer people may start but many may use more once legalized.

4) Life-Cycle Rates

  • Definition: Life-Cycle Rates reflect how the likelihood of drug use changes with age.
  • Pattern observed (roughly, historically):
    • Youth (12–17): relatively low use
    • Young adults (18–25): extremely high use
    • 26–34: begins to decline
    • 35+: declines further
  • Contrast: Legal drug use tends to be spread more evenly across ages; illicit drug use tends to peak in late adolescence and decline into mature adulthood.

4) Life-Cycle Rates: Table 1-2 (Illicit Drug and Alcohol Use by Age, 2011)

  • The table provides past-month use for various categories by age group (12–13, 14–15, 16–17, 18–20, 21–25, 26–34, 35+).
  • Observed patterns (selected representative values, all percentages; values rounded):
    • Any Illicit Drug Past Month:
    • 12–13: ~7.1%
    • 14–15: ~18.7%
    • 16–17: ~30.2%
    • 18–20: ~38.7%
    • 21–25: ~32.9%
    • 26–34: ~21.4%
    • 35+: ~8.5%
    • Drug Other Than Marijuana (Past Month):
    • 12–13: ~3.3%
    • 14–15: ~9.2%
    • 16–17: ~17.2%
    • 18–20: ~23.8%
    • 21–25: ~19.9%
    • 26–34: ~12.9%
    • 35+: ~4.9%
    • Alcohol (Past Month):
    • 12–13: ~7.7%
    • 14–15: ~26.3%
    • 16–17: ~47.8%
    • 18–20: ~66.5%
    • 21–25: ~83.9%
    • 26–34: ~79.2%
    • 35+: ~66.8%
    • Binge Alcohol (Past Month):
    • 12–13: ~2.5%
    • 14–15: ~11.3%
    • 16–17: ~25.3%
    • 18–20: ~46.8%
    • 21–25: ~69.7%
    • 26–34: ~63.8%
    • 35+: ~53.1%
    • Consumption (units/measure; year/month indicators):
    • 12–13: ~1.1
    • 14–15: ~5.7
    • 16–17: ~15.0
    • 18–20: ~31.2
    • 21–25: ~45.4
    • 26–34: ~35.7
    • 35+: ~18.7
  • Source: Results from the 2011 National Survey on Drug Use and Health: National Findings, Detailed Tables, SAMHSA (2012).

Notes on Tables and Figures

  • Figure 16: Past Year Illicit Drug Use by Race/Ethnicity (12+), 2021
    • Estimates vary by group; include note on precision (some groups have low precision; 99% confidence intervals used for error bars).
  • Figure 17: Past Year Marijuana Use by Race/Ethnicity (12+), 2021
    • Similar interpretation notes as Figure 16.
  • Table 1.3: Illicit Drug, Marijuana, Cocaine, and Crack Use (Past Year, 12+), by Race/Ethnicity, NSDUH 2021
    • Totals and subgroups with standard errors in parentheses; provides specific percentages for drug categories by race/ethnicity.
    • Example entries (Past Year):
    • TOTAL illicit drug use: 21.9% (0.33)
    • Marijuana use: 18.7% (0.32)
    • Cocaine use: 1.7% (0.09)
    • Crack use: 0.4% (0.05)
    • By race/ethnicity (Past Year Illicit Drug Use):
    • AIAN: 36.1% (4.17) illicit drugs; 35.0% (4.14) marijuana
    • Multiracial: 34.6% (2.25) illicit drugs; 30.7% (2.18) marijuana
    • Black: 24.3% (0.85) illicit drugs; 21.3% (0.83) marijuana
    • White: 22.5% (0.42) illicit drugs; 19.5% (0.41) marijuana
    • Hispanic/Latino: 19.4% (0.73) illicit drugs; 15.8% (0.68) marijuana
    • Asian: 11.1% (0.98) illicit drugs; 8.6% (0.89) marijuana
    • Note on precision: Some cells have low precision and are marked with an asterisk or omitted.

Antecedents, Influences, and Practical Implications (Summary)

  • Antecedents are pre-event factors; they precede initiation but are not declared as causes.
  • Multilevel influences imply that interventions can target multiple layers (individual, family, school, peers, media, laws, etc.).
  • Understanding prevalence, continuance, consumption, and life-cycle patterns informs policy (e.g., targeting peak-risk ages, focusing on heavy-use groups, and balancing prevention with treatment).
  • Ethical and practical implications: recognizing data limitations (e.g., accuracy, precision by subgroup) and avoiding simplistic causal inferences from correlational data.